Abstract: Maleimide-functionalized closo-dodecaborate (MID) and isothiocyanate-functionalized closododecaborate (ISD) were synthesized from closo-dodecaborate via ring opening reaction of 1,4-dioxane-closodedecaborate complex 1 with ammonia. MID was found to possess highest conjugation efficacy to bovine serum albumin among three closo-dodecaborate derivatives, MID, ISD, and 1. The conjugation reaction of MID to human serum albumin (HSA) proceeded under PBS buffer conditions (pH 7.4). Boron distribution studies in colon 26 tumor-bearing mice revealed that HSA-MID was highly accumulated in tumor (23 ppm B), whereas boron concentrations in other organs such as liver, kidney and spleen were low (3 ~ 8 ppm B).
Introduction
Boron neutron capture therapy (BNCT) has been attracting growing interest as one of the minimally invasive cancer therapies. BNCT uses the nuclear reaction between low-energy thermal neutron (0.025 eV) and boron-10 ( 10 B), and the generated α-particle and lithium nuclei are high linear energy transfer (LET) particles (2.4 MeV) that are sufficiently powerful to kill cells. Furthermore, as the distance traveled by these LET particles is equivalent to a cell's diameter (approximately 5-9 μm), the selective delivery of 10 B atoms to tumor is essential for effective BNCT [1] [2] [3] [4] . Di-sodium salt of mercaptoundecahydrododecaborate (Na 2 [B 12 H 11 SH]) [5, 6] and L-p-boronophenylalanine (L-BPA) [7, 8] have been used in BNCT for many years. L-BPA, in particular, has been widely used for the treatment of not only melanoma but also brain tumor [3, 4] and head and neck cancer [9] [10] [11] because it can be taken up selectively by tumor cells through an amino acid transporter (LAT1) [12] . The accelerator-based BNCT is now undergoing phase II clinical study for the treatment of patient with brain tumor and head and neck cancers in Japan [13] . However, development of new boron carriers is still strongly demanded for patients who have a negative response to L-BPA [14] .
Recently, nano carrier-based boron delivery system, such as liposomes [15] [16] [17] [18] , micelles [19, 20] , and nano tubes [21, 22] , has been developed in order to achieve efficient BNCT. We focused on a serum albumin as a nano biocarrier. Serum albumin, a major plasma protein constituent, is composed approximately 55 % of the human plasma proteins. Albumin is known to accumulate in malignant and inflamed tissues due to enhanced permeability and retention (EPR) effect [23] . Furthermore, it has been observed that tumor is the major site of serum albumin catabolism [24] , thus serum albumin has been extensively investigated as a versatile carrier for therapeutic and diagnostic agents, including diabetes, cancer, rheumatoid arthritis and infectious diseases [25, 26] . For example, Abraxane ® , an albumin-paclitaxel nanoparticle, is the most advanced drug delivery product first approved by FDA in 2005 for the treatment of metastatic breast cancer. Furthermore, albumin microspheres have been investigated in controlled release systems as vehicles for delivery of therapeutic agents to local sites [27] . Based on these observations, we developed maleimide-functionalized closo-dodecaborate (MID; Fig. 1 ) for conjugation to bovine serum albumin (BSA) [28] . BSA contains 35 Cys residues and 17 disulfide bridges, and Cys34 is the only free residue among them. Surprisingly, MID was found to conjugate not only to free SH of cysteine residue but also to lysine residues in BSA under physiological conditions. The highly boronated BSA showed high and selective accumulation in tumor and significant BNCT effect was observed in colon 26 tumor-bearing mice after thermal neutron irradiation.
In this paper, we synthesized isothiocyanate-functionalized closo-dodecaborate (ISD; Fig. 1 ) as an alternative conjugation system for protein functionalization and compared conjugation efficacy between ISD and MID toward albumin. Furthermore, we introduced MID into human serum albumin (HSA) and demonstrated boron distribution in tumor-bearing mice.
Results and discussion
Chemistry 1,4-Dioxane-closo-dodecaborate complex 1 [29] is an important intermediate for both synthesis of MID and ISD. In our previous report, amine 2 was synthesized by the ring opening of 1,4-dioxane-closo-dodecaborate complex 1 of closo-dodecaborate with tetrabutylammonium azide followed by Staudinger reduction [28, 30] . We found that the ring opening of 1,4-dioxane-closo-dodecaborate 1 with ammonia was more efficient to synthesize amine 2 [31, 32] . Indeed, the tetrabutylammonium (TBA) salt of amine 2 was simply purified by recrystallization from methanol. It was converted to its di-TBA salt in 10 % TBAOH in methanol and then reacted with 4-maleimidebutylic acid in the presence of EDCI using NaHCO 3 as a base in acetonitrile to afford di-TBA salt of MID. The counter cation of TBA was sequentially converted to the di-tetramethylammonium followed by the di-sodium form according to our previously reported procedure [28] (Scheme 1).
On the other hand, ISD was also synthesized from amine 2 as shown in Scheme 2. The tetrabutylammonium (TBA) salt of amine 2 was treated with 1,1′-thiocarbonyldiimidazole (TCDI) in the presence of triethylamine (TEA) in dichloromethane to give the di-TBA salt of ISD, which was converted to di-sodium salt through tetramethylammonium (TMA) counter cation.
Conjugation efficacy of MID, ISD, and 1,4-dioxane-closo-dodecaborate complex 1 to BSA It has been reported that 1,4-dioxane-closo-dodecaborate complex 1 undergoes the ring-opening reaction with various nucleophiles including amino acids. Thus, we first examined the conjugation efficacy of MID, ISD, and 1 to BSA. The conjugation reactions of MID, ISD, and 1 to BSA were carried out in PBS buffer (pH 7.4) at room temperature for 1 h and the resulting albumin-closo-dodecaborate conjugates were detected by Western blot analysis using anti-BSH antibody. The results are shown in Fig. 2 . The conjugation efficacy of MID to BSA was higher than that of ISD, although an isothiocyanate group is widely used for protein modification at Lys residue. We previously reported that the maleimide group of MID was conjugated not only to SH free Cys residue but also an amino group of Lys residue [28] . In general, common maleimide compounds do not react with a nucleophilic amino group of Lys residue that is protonated under physiological conditions (pH 7.4). In the case of MID, MID contains negatively charged boron cluster in the molecule associated with sodium counter cations. In the local environment in proteins, the protonated amino group of Lys is probably deprotonated with the negatively charged boron cluster to induce the nucleophilicity. Therefore, the Michael reaction proceeded between the amino group of Lys residue and the maleimide moiety of MID. Interestingly, conjugation of 1,4-dioxane-closo-dodecaborate complex 1 to BSA was also observed under the physiological conditions although the conjugation efficacy was not very high. These results indicate that MID possesses the most promising conjugation efficacy among three closo-dodecaborate derivatives synthesized.
SEM image of albumin-MID conjugates
Nanoparticles albumin-bound technology using high-pressure homogenizers [33] has been used to make albumin nanoparticles of 100-200 nm. In particular, Abraxane ® was reported to form albumin-paclitaxel nanoparticles with a mean particle size of 130 nm. In the current study, a self-assembly method was used to make BSA-MID nanoparticles. As shown in Fig. 3 , albumin-MID conjugates were found to be almost spherical with size distribution from 36 to 52 nm in diameter by field-emission scanning electron microscopy (FE-SEM) analysis.
Conjugation of MID to BSA and HSA
We compared the conjugation efficacy of MID to BSA and human serum albumin (HSA) by Western blot analysis. The conjugation reactions of MID to BSA and HSA were carried out in PBS buffer (pH 7.4) at room temperature for 1 h and the resulting albumin-closo-dodecaborate conjugates were detected by Western blot analysis using anti-BSH antibody. Expectedly, as shown in Fig. 4 , the conjugation reaction of MID to HSA proceeded in a similar manner to BSA under PBS buffer conditions (pH 7.4). In addition, the use of 10 equiv. of MID against HSA showed more effective conjugation than the use of 1 equiv. of MID. Fig. 4 : Western blot analysis of the conjugation efficacy of MID to BSA and HSA. MID (1 mM) was reacted with BSA (0.1 mM) or HSA (0.1 mM) in PBS buffer at pH 7.4 for 1 h, and the resulting mixture was subjected to PAGE. Western blot analysis of BSA-and HSA-closo-dodecaborate conjugates was carried out using anti-BSH antibody. 
Biodistribution of HSA-MID conjugates in tumor-bearing mice

Conclusion
We succeeded in the synthesis of MID and ISD from closo-dodecaborate via 1,4-dioxane-closo-dedecaborate complex 1. Simple synthetic method of amine 2 was established by ring opening reaction of 1 with ammonia. MID was found to possess highest conjugation efficacy to BSA among three closo-dodecaborate derivatives, MID, ISD, and 1. The conjugation reaction of MID to HSA proceeded in a similar manner under PBS buffer conditions (pH 7.4). In addition, the use of 10 equiv. of MID against HSA was more effectively conjugated to HSA than the use of 1 equiv. of MID. Boron distribution study of MID-HSA in colon 26 tumor-bearing mice revealed that HSA-MID was highly accumulated in tumor (23 ppm B) whereas boron concentrations in other organs such as liver, kidney and spleen were relatively low (3 ~ 8 ppm B) . In contrast, rapid clearance from organs was observed in the case of HSA-Na 2 B 12 H 12 , HSA-Na 2 BSH, and HSA-NaB 12 H 11 NH 3 . Therefore, HSA-MID conjugates are considered to be promising boron carriers for BNCT. Further studies for conjugation site identification are now in progress in our laboratory.
Experimental Chemicals
Analytical thin layer chromatography (TLC) was performed on glass plates of silica gel 60 GF 254 (Merck & Co., Inc., Kenilworth, New Jersey, USA), which were visualized by an aqueous alkaline KMnO 4 solution or an acid PdCl 2 solution followed by heating. Column chromatography was conducted on silica gel (Merck Kieselgel 70-230 mesh). Chemicals purchased from commercial sources were used without further purification. (Et 3 NH) 2 C-NMR spectra were recorded on a Bruker AVANCE-400 (400 MHz) and 11 B-NMR spectra were recorded on a ASCEND-500 (160 MHz). Synthetic procedures of compound 3 and MID were reported previously.
Synthesis of di-tetrabutylammonium 4-aminoethoxyethoxy-closo-dodecaborate 2
This compound was synthesized according to the literature procedure. Briefly, to 1,4-dioxane-closododecaborate complex 1 (1 g, 2.12 mmol) in CH 3 CN (8 mL) was added 25 % NH 3 aq. (4 mL NH 3 , 105 mmol), and the mixture was stirred at 50 °C for 11 h. The reaction mixture was cooled to room temperature and then concentrated under reduced pressure. The corresponding ring-opening product was obtained as a white solid. The resulting product was suspended in MeOH and 10 % (w/w) TBAOH in MeOH (6.73 mL, 2.54 mmol) was added. The mixture was stirred until the white solid was dissolved into the MeOH solution. After removing the solvent under reduced pressure, the residue was dissolved CH 2 Cl 2 and washed with distillated water 3 times. The CH 2 Cl 2 phase was dried over MgSO 4 anhydride and concentrated to give amine 2 as a white solid 
Synthesis of di-tetramethylammmonium salt of isothiocyanate-conujugated dodecaborate (4)
To a solution of amine 2 (0.40 g, 0.55 mmol) in CH 2 Cl 2 were added 1,1′-thiocarbonyldiimidazole (TCDI; 0.130 g, 0.730 mmol) and tetraethylamine (0.152 mL, 1.10 mmol) and the mixture was stirred at room temperature for overnight. The organic solvent was removed under reduced pressure and the residue was purified by column chromatography on silica gel (CH 2 
Synthesis of di-sodium salt of isothiocyanate-conujugated dodecaborate (ISD)
Compound 4 (0.522 g, 1.20 mmol) was dissolved in water (50 mL) and Amberlite Na + form (20 g) was added. The mixture was stirred at ambient temperature for 12 h then the resin was removed by filtration. The filtrate was concentrated and freeze-dried to give ISD (0.329 g, 83 %) as a hygroscopic white solid: 1 
FE-SEM analysis of MID-albumin conjugates
The morphology of MID-albumin conjugates was measured by FE-SEM (Hitachi SEM S-5500, Tokyo, Japan) at an accelerating voltage of 5.0 kV. Dried MID-albumin conjugates were placed on double-side carbon tape and then sputter-coated with gold-palladium in an argon atmosphere using a Hummer I sputter coater (Anatech Ltd. St. Alexandria, VA, USA). (MID, ISD, and 1,4 -dioxane-closo-dodecaborate complex 1) to selum albumin and Western blot analysis BSA (0.1 mM, Sigma-Aldrich, St. Louis, USA) was reacted with MID (1.0 mM), ISD (1.0 mM), or 1 (1.0 mM) to BSA in PBS (50 μL) at ambient temperature for 1 h. The mixture was subjected to SDS-polyacrylamide gel electrophoresis (PAGE), transferred to polyvinyliden difluoride (PVDF) membrane (GE Healthcare, Buckinghamshire, UK), and immunoblotted with anti-B 12 H 11 SH (BSH) antibody. After further incubation with horseradish peroxidase (HRP)-conjugated secondary antibody, the membrane was treated with ECL kit (GE Healthcare, Buckinghamshire, UK) and closo-dodecaborate-conjugated BSAs were visualized with a Molecular Imager ChemiDoc XRS System (Bio-Rad, Hercules, CA, USA). Total proteins (closo-dodecaborate-conjugated and unreacted BSA) were visualized by coomassie brilliant blue (CBB) staining. Conjugation of MID to HSA (Sigma-Aldrich, St. Louis, USA) was also carried out in a similar to conjugation to BSA.
Conjugation of closo-dodecaborates
Biodistribution of HSA-Na 2 B 12 H 12 , HSA-Na 2 BSH, HSA-NaB 12 H 11 NH 3 , and HSA-MID in the colon 26 cancer-bearing mice Tumor-bearing mice (Balb/c female, 5-6 weeks old, 16-20 g, Sankyo Labo Service Co., Japan) were prepared by injecting subcutaneously (s.c.) a suspension (1.0 × 10 6 cells/mouse) of colon 26 cells directly into the right thigh. The mice were kept on a regular chow diet and water and maintained under 12 h light/dark cycle in an ambient atmosphere. When the tumor diameter was 7-9 mm, the mice were injected via the tail vein with a 200 μL solution of HSA-Na 2 (30 mg [B]/kg). The mice were lightly anesthetized and blood samples were collected from the retro-orbital sinus at 12 h after administration. The mice were then sacrificed by cervical dislocation and dissected. Liver, kidney, spleen, brain, and tumor were excised, washed with 0.9 % NaCl solution, and weighed. The excised organs were digested with 2 mL of conc. HNO 3 (ultratrace analysis grade, Wako, Japan) at 90 °C for 1-3 h, and then the digested samples were diluted with distilled water. After filtering through a hydrophobic filter, boron concentration was measured by ICP-OES (Thermo Fisher Scientific Inc. Waltham, MA, USA). All protocols were approved by the Institutional Animal Care and Use Committee of Tokyo Institute of Technology.
